Maytansine (1) is a very potent antitumor agent originally isolated by Kupchan and coworkers from the plant, Maytenus serrata (formerly M. ovatus), where it occurs in extremely low concentration (0.00002 percent of dry weight). Its isolation was only possible by virtue of its extraordinary biological potency, using a rigorous bioassay-guided fractionation. 1 and a number of congeners, mostly with variations in the ester side chain, were also isolated from other plants of the family Celastraceae, the highest concentration (12 mg/kg dry weight) being found in Putterlickia verrucosa. Notably, members of the maytansinoid family, the ansamitocins, were subsequently isolated from cultures of Nocardia species as well as some other Actinomycetes, raising the question whether the compounds isolated from the plant materials were produced by the plants or by symbiotic or contaminating microorganisms. The latter possibility was further reinforced by the isolation of maytansinoids from several mosses. Despite its extraordinary potency as an antitumor agent, clinical trials of 1 as an anticancer drug gave disappointing results due to dose limiting toxicity. Structure-activity studies, limited to the naturally occurring compounds and those accessible by semisynthesis from them, did not result in significant improvements of the therapeutic ratio. However, these structural variations were of necessity limited primarily to the C-3 ester side chain and the region around its attachment site; backbone modifications and functional group modifications in other regions of the molecule have remained largely unexplored due to inaccessibility of the compounds. This provides the ultimate rationale for the proposed project. Under this project, the PI will delineate, at the biochemical and at the genetic level, the biosynthesis of the microbial maytansinoids, the ansamitocins. The complete sequence analysis of the ansamitocins biosynthetic gene cluster will then lay the foundation for the engineering of mutant organisms harboring and expressing altered clusters in which specific biosynthetic genes have been deleted, added or replaced by functional equivalents from other biosynthetic pathways. These will be analyzed for the production of analogs of the natural maytansinoid structures. Secondly, the microbial maytansinoid biosynthesis genes and their sequences will be used to analyze the DNA of 1-producing plants and of microorganisms isolated form them for the presence of homologous genes in order to identify the true biosynthetic origin of the maytansinoid structures isolated from these plants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA076461-04
Application #
6329018
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Program Officer
Fu, Yali
Project Start
1998-01-15
Project End
2002-07-21
Budget Start
2000-12-01
Budget End
2002-07-21
Support Year
4
Fiscal Year
2001
Total Cost
$228,983
Indirect Cost
Name
University of Washington
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Eichner, Simone; Eichner, Timo; Floss, Heinz G et al. (2012) Broad substrate specificity of the amide synthase in S. hygroscopicus--new 20-membered macrolactones derived from geldanamycin. J Am Chem Soc 134:1673-9
Wu, Yingying; Kang, Qianjin; Shang, Guangdong et al. (2011) N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis. Chembiochem 12:1759-66
Rui, Zhe; Petrícková, Katerina; Skanta, Frantisek et al. (2010) Biochemical and genetic insights into asukamycin biosynthesis. J Biol Chem 285:24915-24
Harmrolfs, Kirsten; Brunjes, Marco; Drager, Gerald et al. (2010) Cyclization of synthetic seco-proansamitocins to ansamitocin macrolactams by Actinosynnema pretiosum as biocatalyst. Chembiochem 11:2517-20
Taft, Florian; Brünjes, Marco; Knobloch, Tobias et al. (2009) Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. J Am Chem Soc 131:3812-3
Kubota, Takaaki; Brunjes, Marco; Frenzel, Thomas et al. (2006) Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum. Chembiochem 7:1221-5
Floss, Heinz G (2006) Combinatorial biosynthesis--potential and problems. J Biotechnol 124:242-57
Wenzel, Silke C; Williamson, Rachel M; Grunanger, Christian et al. (2006) On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of ""glycolate"" units into ansamitocin and soraphen A. J Am Chem Soc 128:14325-36
Liu, Zhongfa; Floss, Heinz G; Cassady, John M et al. (2004) An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. J Pharm Biomed Anal 36:815-21
Spiteller, Peter; Bai, Linquan; Shang, Guangdong et al. (2003) The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum. J Am Chem Soc 125:14236-7

Showing the most recent 10 out of 15 publications